Jubilant Therapeutics
↗Bedminster, NJ, United States
Jubilant Therapeutics is a patient-centric biopharmaceutical company advancing potent and selective small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases. Founded in 2019 as a carve-out from parent company Jubilant Pharmova Limited, the company operates as an independent U.S.-based biotech venture with global operations. The company focuses on differentiated, orally bioavailable molecules addressing both validated and novel therapeutic targets in oncology and immunology.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Oncology and Autoimmune Therapeutics
SIZE & FINANCIALS
Employees:11-50
Founded:2019
Ownership:private
Status:operating
FUNDING
Stage:Private (undisclosed funding)
Investors:Jubilant Pharmova Limited (parent company)
PIPELINE
Stage:Phase I/II Clinical
Lead Drug Stage:Phase I/II (JBI-802)
Modalities:Small molecule, Oral bioavailable compounds
Active Trials:2
Trial Phases:Phase 1: 2 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Jubilant Pharmova Limited (Jubilant Bhartia Group)
Key Partnerships:The Wistar Institute (PAD4 cancer research collaboration), Multiple CRO partnerships for clinical trial execution
COMPETITION
Position:Emerging (early-stage with novel dual-mechanism approach)
Competitors:Syndax Pharmaceuticals (LSD1 inhibitors), Constellation Pharmaceuticals (HDAC inhibitors), Forma Therapeutics (epigenetic modulators), Other PAD4 inhibitor developers, Various PRMT5 inhibitor programs (GSK, others)
LEADERSHIP
Key Executives:
Daniel J. O'Connor - President & Chief Executive Officer
Shyam Pattabiraman - Vice President & Chief Financial Officer
Melda Dolan - Chief Medical Officer
Sridharan Rajagopal (Raj) - Vice President & Head of Medicinal Chemistry
Maggie Aimone - Executive Assistant
Scientific Founders:Luca Rastelli (Chief Scientific Officer - noted as key scientific leader)
Board Members:Hari S Bhartia (Board Member, Jubilant Bhartia Group CFO), Dr. Leila Alland (Board Member - CMO of PMV Pharmaceuticals, p53 precision oncology expert), Arvind Chokhany (Board Member - 25+ years in major financial institutions), Robert Glassman (Board Member), Nadir Patel (Independent Board Member - government affairs and corporate advisory background)
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Jubilant Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Jubilant Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.